[Carbohydrate antigen CA 19-9: value in pancreatic pathology].
In order to determine the diagnostic usefulness of the dosage of carbohydrate antigen (CA 19-9) serum levels in pancreatic diseases, 38 patients with pancreatic lesions proved at laparotomy were studied. Pancreatic lesions were classified into two groups: a) group I: pancreatic adenocarcinoma (17 cases) b) group II: benign pancreatic diseases (21 cases). CA 19-9 serum levels were statistically higher in patients of the first group (p less than 0.001). All patients except one with CA 19-9 higher than 60 U/ml had pancreatic carcinoma. All patients except two with CA 19-9 less than 60 U/ml had a benign lesion. The sensitivity and specificity of CA 19-9 were 88 and 95 p. 100 respectively. These results show that CA 19-9 dosage is useful in distinguishing between benign and malign lesions of the pancreas.
Venot
J
J
Vincent
D
D
Gainant
A
A
Descottes
B
B
Cessot
F
F
Beck
C
C
D000230:Adenocarcinoma / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D006801:Humans; D010182:Pancreatic Diseases / Q000175:diagnosis / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000276:immunology*; D011863:Radioimmunoassay; D012698:Serologic Tests
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate
L'antigène carbohydrate CA 19-9: intérêt au cours de la pathologie pancréatique.